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SUMMARY
Long-acting/extended release drug formulations have proved very successful in diverse areas of 
medicine including contraception, psychiatry, and most recently, HIV disease. While challenging, 
application of this technology to TB treatment could have substantial impact. The length of 
treatment required for all forms of TB put existing regimens at risk for failure because of early 
discontinuations and treatment default. Long-acting injections, for example administered monthly, 
could improve patient adherence and treatment outcomes. We review the state of the science for 
potential long-acting formulations of existing TB drugs, and propose a Target Product Profile for 
new formulations to treat latent TB infection. The physicochemical properties of some TB drugs 
make them unsuitable for long-acting formulation, but there are promising candidates that have 
been identified through modeling and simulation, and other novel agents and formulations in 
preclinical testing. An efficacious long-acting treatment for latent TB infection, particularly for 
those co-infected with HIV, and if coupled with a biomarker to target those at highest risk for 
disease progression, would be an important tool to accelerate progress towards TB elimination.
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INTRODUCTION
The World Health Organization (WHO) strategy to end the global tuberculosis (TB) 
epidemic can only be accomplished by dramatic acceleration of early diagnosis of TB, 
preventive treatment of those at risk for disease progression, and treatment of all patients 
with TB.1 Of the 23% of the world’s population allegedly infected with latent tuberculosis 
infection (LTBI), less than 5% are diagnosed and treated, therefore diagnosis and 
management of LTBI is a crucial intervention for TB elimination.2,3 Reasons for poor 
uptake of isoniazid preventive therapy (IPT) include the length of treatment, risk of side 
effects, perceived risk of development of drug-resistant TB, lack of acceptance by persons at 
risk, and suboptimal completion rates.4 Because of the poor positive predictive value of the 
current screening tests, the large number of people needed to treat prevent a case of TB is 
also an obstacle.5
Of all the risk factors for TB disease progression, human immunodeficiency virus (HIV) co-
infection is the most powerful predictor. TB is the leading cause of death in HIV-infected 
persons worldwide, and this has persisted despite the fact that provision of antiretroviral 
therapy (ART) is increasing - three quarters of co-infected patients with HIV and TB 
received ART in 2014.6 Globally, HIV-infected persons account for 12% of people who 
develop TB annually, and 25% of deaths from TB.7
People infected with TB but not HIV have an average 10% lifetime risk of developing TB 
disease, and there is a growing research portfolio investigating biomarkers to identify those 
at highest risk.8 Transcriptional biomarkers and T-cell activation markers are showing 
promise, as are sophisticated imaging techniques such as positron emission tomography.9–11 
Better diagnostic and prognostic tools will enable targeted preventive therapy for those at 
high risk of disease progression.
Preventive therapy is effective. In a Cochrane Database review of 12 randomized clinical 
trials of LTBI treatment in 8578 randomized HIV-infected persons, preventive therapy with 
any anti-TB drugs administered for 6–12 months versus placebo resulted in an overall 32% 
reduction in the incidence of active TB (relative risk [RR] 0.68; 95% confidence interval 
[CI] 0.54, 0.85).12 The effect was greater for those with a positive TB skin test (TST) (62% 
reduction; RR 0.38; [95% CI 0.25, 0.57]) than for those with a negative TST (11% 
reduction; RR 0.89; [95% CI 0.64, 1.24]). Three months of weekly rifapentine and isoniazid 
(3HP) is as effective as 9 months of isoniazid, and had higher completion rates (82% versus 
69%, p<0.001).13 This regimen is also safe and effective in HIV-infected persons, although 
not on antiretroviral therapy, and was better tolerated with higher completion rates than 9 
months of isoniazid.14
Drug-drug interactions are important considerations, especially for HIV-infected persons on 
antiretroviral therapy but co-treatment is possible.15 For orally administered drugs, 
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bioavailability is limited by drug transporter proteins (E.g. ABC transporters such a P-
glycoprotein) and metabolic enzymes (E.g. cytochrome P450 isoforms) within the intestinal 
epithelium and during first-pass through the liver via the hepatic portal vein. Moreover, the 
expression and activity of many of these proteins is governed by variants in genes coding for 
them or their transcriptional regulators, and these same proteins are important mediators of 
many pharmacokinetic drug-drug interactions seen clinically. Since parenteral delivery 
avoids the gastrointestinal tract and first pass metabolism, it is conceivable that the 
magnitude of some transporter or enzyme-mediated drug-drug interactions or 
pharmacogenetic variability may be less with long-acting formulations, but this remains to 
be seen and will require careful evaluation.16
Background on LA therapy
The term long-acting (LA) has been employed in drug delivery to cover applications in oral 
and parenteral administration, and has historically not been defined by an explicit duration 
of pharmacokinetic exposure. Notably, the term was previously employed for once-daily oral 
formats for insulin17 which is clearly not the ambition for the recent developments, where 
the goal is to achieve therapeutic exposure for periods ranging from weeks to months. 
Recently, it was proposed that a candidate should achieve at least once weekly, once 
monthly, or once 6-monthly dosing to qualify as LA when considering oral, injection, or 
implant, respectively, in the context of HIV.16 Thus, the application of the term should be 
strongly considered in the context of the specific indication for which a new medicine is 
being developed, and for TB this has informed the target product profile (TPP) discussed 
below.
The convenience and durability of LA drug formulations has provided substantial benefit to 
diverse areas of human health. The extended duration of drug delivery conferred by these 
formulations leads to improved adherence and, as a consequence, to improved outcomes. 
Broadly, LA injectable medicines have been explored utilizing either intramuscular or 
subcutaneous administration of oil-based solutions, drug-encapsulated in polymer 
microparticles, in-situ formation of gels or solid/semi-solid structures, or drug particle 
suspensions.16 The recent paradigm for LA injectables has emerged from the delivery of 
antipsychotic drugs such as paliperidone palmitate,18 which involve intramuscular 
administration of solid drug nanoparticle (SDN) suspensions. Indeed, the exciting new 
developments for HIV prevention and therapy have involved the formation of SDNs of 
rilpivirine and cabotegravir, by the process of wet-bead milling.19,20 These formulations are 
spearheading the advent of LA injectables for infectious diseases, and provide between 1 
month and 3 months of therapeutic exposure from a single intramuscular depot. The two-
drug combination of injectable long-acting cabotegravir with rilpivirine every 4 weeks or 
every 8 weeks was recently shown to be as effective as daily three-drug oral therapy at 
maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.
21
 Work in HIV disease has been encouraged by the early accreditation of patient 
acceptability, which indicated that of 400 adult patients with HIV infection surveyed in the 
US, 84% indicated they would or probably try an injectable nanoformulated antiretroviral 
therapy that provided monthly administration.22 This early indication of patient acceptability 
has also been born out through attitudes surveys imbedded within subsequent clinical trials, 
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and is likely to be driven by the well-recognized issues of treatment-fatigue, which 
subsequently drive patient non-adherence and its associated consequences.
Suitability of TB drugs for LA formulation
Clearly the development of LA injectable formulations is highly dependent on the specific 
clinical needs, and so far, the approach has focused predominantly on indications that 
require chronic dosing. There are clear paradigms shared between HIV and TB therapy, such 
as the need for delivery of drug combinations, concerns regarding emergence of resistance, 
and issues with adherence to medication. Moreover, the potential for a single administration 
providing a “one shot cure” is an almost irresistible ambition for future TB treatment, which 
should also prove extremely compatible with directly observed therapy (DOT). In addition, 
it is tempting to speculate that avoiding oral delivery and associated first pass metabolism 
through the liver may bring additional benefits in terms of drug-drug interactions, which 
have complicated TB therapy for decades. Importantly, all the existing LA injectable 
formulations (across indications) have been developed using drugs first approved for oral 
administration. While this has inevitably precluded the robust evaluation of the critical 
physicochemical properties required for the approach, it is encouraging that existing drugs 
may be LA-enabled by reformulation, and this may also simplify the regulatory pathway. 
However, the development of LA injectables for TB requires that either the existing drugs be 
compatible with the advanced formulation technologies, or that new drugs be developed 
specifically for such applications.
Existing LA injectable drugs are characterized by specific pharmacokinetic and 
pharmacodynamic properties which support their compatibility with the approach. In 
addition to the obvious need for favorable safety profiles, formation of drug nanoparticle 
suspensions requires low aqueous solubility (water-soluble nanoparticles rapidly dissolve 
and release drug), high potency (to minimize the requirement for high plasma 
concentrations), and long pharmacokinetic half-lives (to minimize rapid clearance). For 
existing TB drugs, these properties are summarized in Table 1, using therapeutic plasma 
concentrations as a surrogate for potency. The drugs were selected based on their common 
usage for LTBI and in first and second therapy, with potential suitability for LA formulation. 
The three key properties (half-life, water solubility and therapeutic concentrations) of 
existing LA injectable drugs are represented in Figure 1, and overlaid with existing anti-TB 
agents. Accordingly, rifapentine, delamanid, bedaquiline and rifabutin have pharmacological 
and physicochemical characteristics that make them potential candidates for LA 
administration using the drug nanoparticle suspension approach (half-life > 12 hours, 
therapeutic concentrations < 1000 ng/mL and water solubility < 50 mg/mL).
TB LEAP activities
A Working Group on LA/ER Formulations for the Prevention and Treatment of TB was 
established in 2015 under the auspices of the Long-Acting/Extended Release Antiretroviral 
Resource Program (LEAP). LEAP was established in 2015 with a 5-year R24 grant from the 
National Institute of Allergy and Infectious Diseases to support established investigators, 
and encourage new investigators working on LA/ER formulations by: 1) encouraging 
scientific innovation through access to a centralized group of subject matter experts in the 
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chemistry, pharmacology, regulation, clinical development, and commercialization of 
LA/ER ARV’s; 2) establishing a communications and data hub for dissemination of 
important data and results from ongoing laboratory and clinical studies as well as facilitation 
of communication amongst investigators and stakeholders; and 3) developing and offering a 
modeling and simulation core of actual and predicted drug concentrations for LA 
formulations to aid investigators in assigning priority to drugs and formulations in 
development (described in full detail at www.longactinghiv.org). The LEAP TB Working 
Group supports development of LA/ER drugs for TB, especially in TB/HIV co-infection. 
This group has led the effort to develop a Target Product Profile (TPP) for anti-TB 
formulations for use in TB prevention, use of the Modelling and Simulation Core to screen 
existing molecules for suitability for LA/ER formulation for the treatment or prevention of 
TB, and hosts an annual meeting to support these activities.
Target product Profile for long-acting drugs for the treatment of latent TB infection
A TPP for LA latent TB treatment was drafted that describes the attributes of the treatment 
that would be ideal as well as the minimally acceptable attributes that would be required in a 
viable regimen (Table 2). These attributes fall under categories that include the anticipated 
efficacy, the number of agents, the presentation of the regimen (volume, number, and 
frequency of administrations), as well as cost and contraindications. While the TPP was 
drafted by the TB LEAP with input from appropriate subject matter experts that weighed in 
on the drug discovery, formulation, clinical, and public policy aspects, it is important to note 
that it is a living document that should evolve with the understanding of the field.
Preliminary Data
Multiple approaches have been investigated for prolonging the dosing interval of both orally 
and parenterally administered anti-TB drugs, although the vast majority of reported data in 
the literature consists of in vitro work, with minimal preclinical data and no clinical 
pharmacology data either in healthy volunteers or in individuals with TB.23 The primary 
focus of sustained release approaches has been the use of novel drug delivery systems and 
reformulations of current available anti-TB drugs. Several explore pulmonary delivery of TB 
drugs as a means to increase drug concentrations at the anatomic site of TB disease.24 
Pulmonary delivery methods have been shown to sustain therapeutic drug levels for 
extended periods of time; for example, a study of rifampin microspheres maintained 
rifampin concentrations above the MIC for 26 days.25 Early parenteral approaches to 
sustained drug delivery involved microsphere and liposomal formulations of anti-TB drugs.
26,27
 Poly lactic-co-glycolic acid (PLGA) and poly (D-L-lactic acid) micro particles have 
been shown to be suitable carriers for both rifampicin and isoniazid, with preclinical data 
suggesting once weekly dosing as a possibility.28,29 Many natural occurring proteins and 
polymers such as the plant protein zein, the collagen degradation product gelatin, as well as 
plant derived alginate and chitosan have been explored as biodegradable, biocompatible slow 
release mechanisms for anti-TB drug delivery.30,31 Oral nanoparticle formulations consisting 
of carriers derived from these agents have demonstrated sustained therapeutic plasma drug 
concentrations of INH/RIF/PZA/EMB for up to 5–7 days in single dose animal models.32 
More recently, the field of TB drug delivery has migrated toward nano-particle formulations, 
summarized by Pandey et al.33
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Using the LEAP modelling core, computational simulations were utilized to simulate 
potential LA administration strategies for four anti-TB agents. Drugs used for latent TB 
and/or having favorable physicochemical/pharmacological properties were selected. The 
modelling approach predicted that 1500 mg of delamanid and 250 mg of rifapentine could 
be sufficient doses for monthly IM administration while bedaquiline and isoniazid would 
require more frequent IM dosing compared to the other two agents. Clearly, these data do 
not provide direct evidence that the drugs can be formulated as an LA injectable, but they do 
provide a potential pharmacological rationale for their assessment.
DISCUSSION
As imperfect adherence and poor completion rates for preventive treatment of latent TB 
infection are major obstacles to the effectiveness of this strategy, an important and novel 
solution to this problem could be the development of long-acting/extended-release injectable 
anti-TB drugs that can be administered periodically in a clinic setting, eliminating the 
problems of suboptimal adherence and treatment completion.34 This strategy may be 
especially important for vulnerable populations, including children, adolescents, and 
pregnant women. Bypassing oral dosing may improve bioavailability, and possibly improve 
tissue penetration although this remains to be established. In addition, incidence of certain 
adverse effects and drug-drug interactions may be decreased. Opportunities and challenges 
presented by LA treatment for TB are summarized in Table 3.
The development of LA products is complex and challenging. Treatment of infectious 
diseases presents unique challenges in particular due the potential for the development of 
drug resistance. To mitigate this risk, drugs used to treat infectious disease are often 
administered at high multiples above their minimally efficacious doses, often at maximally 
tolerated doses, and are frequently used in regimens containing multiple agents. This can be 
at odds with the development of LA formulations where the ideal is a minimal number of 
drugs that can be administered at low doses that minimizes the size (and therefore 
invasiveness) of the parenterally administered regimen and that provides the maximal 
duration of drug delivery. Thus far, all successful LA agents are administered separately. LA 
cabotegravir and rilpivirine have proved very successful in clinical trials for HIV treatment, 
but the drugs are still given as two separate intramuscular injections.35 To date, most LA 
injectables have been developed from existing oral formulations although the 
physicochemical properties of many compounds render them unsuitable for this approach. 
This is especially true for existing oral anti-TB drugs, many of which lack the right balance 
of water solubilty, lipophilicity, half-life and potency.16 Management of adverse effects may 
be more challenging with LA injectable formulations as they cannot be immediately 
discontinued, and the physicochemical properties that make them suitable for LA injectables 
also negate the option of dialysis or other strategies to remove the drug. New drug delivery 
technologies, such as removable solid or semi-solid implants, may alleviate many of these 
problems by providing options that are readily removable.36
Robust in vitro and in silico methods are being developed to investigate the potential of LA 
TB treatment, and animal models are also needed. Preclinical research on the therapeutic 
potential of new TB drugs and regimens relies heavily on mouse infection models. While 
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these models provide useful information about efficacy, data about important 
pharmacokinetic/pharmacodynamic relationships may be lacking and can only be 
established from large and costly trials in humans.37,38
The TB LEAP group is first focusing on development of LA anti-TB treatment for latent 
infection, which presents an attractive target since there is a reasonably high likelihood that 
its treatment with a single agent would be efficacious in due to the relatively low 
mycobacterial burden. However, successful LA TB drugs could also have important 
applications for treatment of both drug sensitive and drug resistant TB disease. For example, 
the development of LA isoniazid and rifampin formulations that could be administered 
monthly would result in the continuation phase of TB treatment being accomplished with 4 
monthly injections. This could have substantial impact on treatment completion rates.
CONCLUSION
LA/ER TB treatment has theoretical potential to dramatically improve adherence to and 
completion of treatment for latent infection. New LA/ER formulations are likely to have 
their most immediate impact on the treatment of LTBI.39 Coupled with a field-friendly 
diagnostic test to identify those at highest risk for progression to disease, an LA/ER TB 
formulation could enable a test-and-treat strategy that would greatly increase the possibility 
of TB eradication.
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Figure 1. 
Schematic representation of the three drug-specific properties influencing physicochemical 
and pharmacological compatibility with LA administration, as described in the main text. 
The grey area represents the range for existing LA formulations for multiple disease areas 
(paliperidone palmitate, olanzapine pamoate, risperidone, medroxyprogesterone acetate, 
rilpivirine and cabotegravir; half-life > 12 hours, therapeutic concentrations < 1000 ng/ml 
and water solubility < 50 mg/ml). Axis span across 0.1 to 10000 (log10 scale). It can be seen 
that rifabutin, rifapentine, delamanid and bedaquiline have properties in the range of other 
LA medicines, whereas other drugs currently used in TB therapy do not.
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Table 2
Target Product Profile for a LA/ER formulation for treatment of latent TB.
Minimal Parenteral Regimen Ideal Parenteral Regimen
Mechanism of Action Activity against drug susceptible TB Activity against drug susceptible and drug 
resistant TB
# of Compounds in the 
Regimen Monotherapy Monotherapy
Indication Treatment of presumed drug susceptible latent TB infection
Treatment of latent TB infection, including for 
contacts of MDRTB
Availability of Drug 
Susceptibility Testing (DST) 
for the Index Case, if known
Rapid, low cost DST method that can be 
implemented at district level or below No requirement for DST
Target Populations Adults & other age groups with regulatory approval; irrespective of HIV or immune status
All age groups, irrespective of HIV status 
(pediatric formulation likely to come after adult 
indication)
Route of Administration IV infusion; IM/SC injection; or implantation IM/SC; or implantation
Product Presentation 2 x 2 ml injections; or an implant Single injection ( ≤2 ml; 25-gauge or smaller); or 
an implant
Dosage Form and Schedule
Suspension administered: 1x per week or less 
frequently for up to 3-months; or 1x per month for ≥6 
months; or implant lasting for up to 3 months
Suspension administered less frequently than 1x 
per month for up to 3-months; or implant lasting 
for up to 1 year
Expected Efficacy Non-inferior to SOC (e.g. RPT/INH - 3mo) Superior to SOC (less incident TB, shorter duration of treatment)
Contraindications, Warnings, 
Precautions, Interactions, and 
Use During Pregnancy and 
Lactation
No additional monitoring required compared with 
current therapy; DDIs no worse than current therapy; 
mild injection site reaction
No contraindications or warnings; no significant 
side effects; no significant DDIs; safe for use in 
pregnant and lactating women; no injection site 
reaction
Shelf-life and Storage 2 yr at 4°C 3 yr at 40°C and 75% humidity
Product Registration and 
WHO Prequalification Approved by FDA, EMA, WHO PQ, and national regulatory authorities of high-burden countries
Cost of Treatment Total health system cost no greater than current Total health system cost less than current
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Table 3
Potential advantages and disadvantages of monthly injectable anti-TB treatment as compared to oral therapy.
Potential Advantage Potential Disadvantage
Reduced inter-individual variability in drug exposures Large injection volume
Dose reduction Difficulty of combing more than one agent
Avoidance of gastrointestinal adverse effects Requirement for oral lead-in
Decreased drug-drug interactions Management of adverse effects
Improved adherence Resistance consequences of missed doses
Compatibility with DOT
Decreased cost
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